Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.

[1]  M. Meng,et al.  Prostate Cancer Predictors of Pathologic Progression on Biopsy Among Men on Active Surveillance for Localized Prostate Cancer : The Value of the Pattern of Surveillance Biopsies , 2013 .

[2]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[3]  K. Pienta,et al.  Risk prediction tool for grade re‐classification in men with favourable‐risk prostate cancer on active surveillance , 2017, BJU international.

[4]  Z. Tandoğdu,et al.  Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. , 2013, European urology.

[5]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[6]  John T. Wei,et al.  Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. , 2016, The Journal of urology.

[7]  Steven J. M. Jones,et al.  A multi-institutional evaluation of active surveillance for low risk prostate cancer. , 2013, The Journal of urology.

[8]  William Hsu,et al.  Utilizing time‐driven activity‐based costing to understand the short‐ and long‐term costs of treating localized, low‐risk prostate cancer , 2015, Cancer.

[9]  M. Roobol,et al.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.

[10]  Mufaddal Mamawala,et al.  Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Trock,et al.  Risk stratification of men choosing surveillance for low risk prostate cancer. , 2009, The Journal of urology.

[12]  A. Billis.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience , 2011 .

[13]  K. Fareed,et al.  More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound Guided Prostate Biopsy. , 2016, The Journal of urology.

[14]  M. Cooperberg,et al.  Active surveillance for the management of prostate cancer in a contemporary cohort , 2008, Cancer.

[15]  Matthew R Cooperberg,et al.  Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Ruth Etzioni,et al.  Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. , 2015, European urology.

[17]  M. Cooperberg,et al.  Active surveillance for prostate cancer: a systematic review of the literature. , 2012, European urology.

[18]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Epstein,et al.  Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.J Clin Oncol. 2015 Oct 20;33(30):3379-85. [Epub 2015 Aug 31]. doi: 10.1200/JCO.2015.62.5764. , 2017, Urologic oncology.